公开(公告)号：US20250051813A1

公开(公告)日：2025-02-13

申请号：US18814011

申请日：2024-08-23

Applicant: Inbiose N.V.

Inventor： Jo Maertens ,  Joeri Beauprez ,  Marjan De Mey

IPC: C12P19/14 ,  C12N9/10 ,  C12N9/26 ,  C12N9/90 ,  C12N15/52 ,  C12N15/70 ,  C12N15/81 ,  C12P19/18 ,  C12P19/30

Abstract: The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.

公开(公告)号：US20240376508A1

公开(公告)日：2024-11-14

申请号：US18782744

申请日：2024-07-24

Applicant: National University Corporation Shizuoka University ,  Osaka Soda Co., Ltd.

Inventor： Nobuyuki Yoshida ,  Kouji Nishikawa ,  Hideaki Idogaki

IPC: C12P19/30 ,  A23L33/10 ,  A61K8/49 ,  A61K31/706 ,  C12N1/20

Abstract: Microorganisms which efficiently produce nicotinamide riboside, and microorganisms which can efficiently produce both nicotinamide mononucleotide and nicotinamide riboside. Nicotinamide mononucleotide and nicotinamide riboside can be produced by culturing lactic acid bacteria belonging to the genus Fructobacillus.

公开(公告)号：US12098403B2

公开(公告)日：2024-09-24

申请号：US17061741

申请日：2020-10-02

Applicant: Inbiose N.V.

Inventor： Jo Maertens ,  Joeri Beauprez ,  Marjan De Mey

IPC: C12P19/14 ,  C12N9/10 ,  C12N9/26 ,  C12N9/90 ,  C12N15/52 ,  C12N15/70 ,  C12N15/81 ,  C12P19/18 ,  C12P19/30

CPC classification number: C12P19/14 ,  C12N9/1051 ,  C12N9/2431 ,  C12N9/90 ,  C12N15/52 ,  C12N15/70 ,  C12N15/81 ,  C12P19/18 ,  C12P19/305 ,  C12Y204/01007 ,  C12Y204/01008 ,  C12Y204/01022 ,  C12Y204/01069 ,  C12Y302/01026 ,  C12Y504/02002

Abstract: The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.

公开(公告)号：US12043863B2

公开(公告)日：2024-07-23

申请号：US17400168

申请日：2021-08-12

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Yuval Ebenstein ,  Micha Fridman

IPC: C12Q1/6806 ,  C12P19/30 ,  G01N21/64

CPC classification number: C12Q1/6806 ,  C12P19/305 ,  G01N21/6428 ,  C12Q1/6827 ,  C12Q2537/164

Abstract: Provided herein is a method of labeling the epigenetic modification 5-hydroxymethyl-cytosine along a DNA molecule that involves attaching a 5-hydroxymethyl-cytosine specific labeling agent to the DNA molecule, which is effected by enzymatically synthesizing UDP-6-N3-Glucose by subjecting 6-azidoglucose to an enzymatic catalysis by N-acetylhexoseamine 1-kinase (NahK) in the presence of ATP to thereby obtain a phosphorylated 6-azidoglucose, followed by subjecting the phosphorylated 6-azidoglucose to enzymatic catalysis by uridyltransferase (GlmU) in the presence of UTP to thereby obtain UDP-6-N3-Glucose, followed by incubating the DNA molecule with UDP-6-N3-Glucose and ß-glucosyltransferase, to thereby obtain a 5-hydroxymethyl-cytosin e glycosylated by a 6-azidoglucose residue in the DNA molecule, and reacting the modified DNA molecule with a labeling agent which is chemically compatible with the azide group of the 6-azidoglucose residue.

公开(公告)号：US20240199675A1

公开(公告)日：2024-06-20

申请号：US18240621

申请日：2023-08-31

Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

Inventor： Geert-Jan Boons ,  Anthony Robert Prudden ,  Lin Liu

IPC: C07H5/06 ,  C12P19/26 ,  C12P19/30

CPC classification number: C07H5/06 ,  C12P19/26 ,  C12P19/305

Abstract: Disclosed herein are oligosaccharides and intermediates useful for the production thereof. The compounds are useful as analytical standards and as intermediates for the preparation of more complex oligosaccharide and N-glycan products. The compounds may be prepared in high purity using the selective stop/go synthetic methods disclosed herein.

公开(公告)号：US20240076309A1

公开(公告)日：2024-03-07

申请号：US18225476

申请日：2023-07-24

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Michael Solomon Goldberg ,  Ellese Carmona

IPC: C07H21/00 ,  A61K35/17 ,  C07K14/505 ,  C12P19/30

CPC classification number: C07H21/00 ,  A61K35/17 ,  C07K14/505 ,  C12P19/30 ,  A61K48/00

Abstract: The present invention provides circularized RNA and methods of making, purifying, and using same.

公开(公告)号：US20230125968A1

公开(公告)日：2023-04-27

申请号：US17974381

申请日：2022-10-26

Applicant: Asahi Kasei Pharma Corporation

Inventor： Takeshi MATSUOKA ,  Tatsuya HIRATA ,  Masaru YAMAKOSHI

IPC: C12P19/30 ,  C12N9/10

Abstract: The present invention addresses the problem of providing a method for producing nicotinamide mononucleotide, that produces nicotinamide mononucleotide using a single enzyme and using nucleoside monophosphate, pyrophosphate, and nicotinamide as starting materials. This problem is solved by a nicotinamide mononucleotide production method that includes at least the following steps 1) and 2): 1) a first step of producing phosphoribosyl diphosphate by the action of substantially one enzyme on nucleoside monophosphate and pyrophosphate; and 2) a second step of producing nicotinamide mononucleotide by the action of only substantially the aforementioned one enzyme on nicotinamide and the phosphoribosyl diphosphate that is the product of the first step.

公开(公告)号：US11041008B2

公开(公告)日：2021-06-22

申请号：US16123431

申请日：2018-09-06

Applicant: the Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services

Inventor： Cristina Bergamaschi ,  Barbara K. Felber ,  George N. Pavlakis ,  Antonio Valentin

IPC: C07K14/54 ,  C07K14/715 ,  C12N15/62 ,  C12P19/30 ,  C12N5/16 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  A61K47/68 ,  A61K38/20 ,  C12N15/09 ,  A61K38/14 ,  A61K38/00 ,  C12N5/07 ,  C12N15/113 ,  C12P21/02

Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.

公开(公告)号：US10894816B2

公开(公告)日：2021-01-19

申请号：US15969647

申请日：2018-05-02

Applicant: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services

Inventor： George N. Pavlakis ,  Barbara K. Felber ,  Antonio Valentin ,  Cristina Bergamaschi

IPC: C07K14/54 ,  C07K14/715 ,  A61K38/20 ,  C12N15/62 ,  C12N5/16 ,  C12P19/30 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  A61K47/68 ,  C12N15/09 ,  A61K38/00 ,  C12N5/07 ,  C12N15/113 ,  C12P21/02

Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.

公开(公告)号：US20200332332A1

公开(公告)日：2020-10-22

申请号：US16832347

申请日：2020-03-27

Applicant: Mitsubishi Chemical Corporation

Inventor： Takanori Akiyama

IPC: C12P19/30 ,  C07H19/048 ,  C12N9/10 ,  C12N9/12

Abstract: An object of the present invention is to provide a method for producing nicotinamide mononucleotide (NMN) with excellent production efficiency. The method for producing NMN according to the present invention (the first aspect) comprises the step of bringing a transformant with enhanced expression of enzymes nicotinamide phosphoribosyltransferase (Nampt), phosphoribosyl pyrophosphate synthetase (Prs) and polyphosphate kinase (Ppk), a cell-free protein synthesis reaction solution having the three enzymes expressed, or a treated product thereof into contact with a mixture containing ribose-5-phosphate (R5P), nicotinamide (NAM), ATP and polyphosphate.